Cargando…

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects

This phase 1, 2‐part, 2‐period, open‐label, drug‐drug interaction study evaluated the potential for pharmacokinetic interactions between upadacitinib and rosuvastatin, an organic anion transporting polypeptide (OATP) 1B1 and breast cancer resistance protein substrate, or atorvastatin, a cytochrome P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohamed, Mohamed‐Eslam F., Coppola, Sheryl, Feng, Tian, Camp, Heidi S., Kim, Elaine, Othman, Ahmed A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596765/ https://www.ncbi.nlm.nih.gov/pubmed/34109764 http://dx.doi.org/10.1002/cpdd.957

Ejemplares similares

The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
por: Trueman, Sheryl, et al.
Publicado: (2019)

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
por: Klünder, Ben, et al.
Publicado: (2017)

Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2020)

Assessment of the Effect of Filgotinib on the Pharmacokinetics of Atorvastatin, Pravastatin, and Rosuvastatin in Healthy Adult Participants
por: Anderson, Kacey, et al.
Publicado: (2021)

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
por: Klünder, Ben, et al.
Publicado: (2019)

Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure‐Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2018)

Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
por: Mohamed, Mohamed-Eslam F., et al.
Publicado: (2019)

Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients
por: Ponce-Bobadilla, Ana Victoria, et al.
Publicado: (2022)

Exposure‐Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis—Analyses of Phase 2b Study to Support Selection of Phase 3 Doses
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2020)

Pharmacokinetics and Genetic Factors of Atorvastatin in Healthy Korean Subjects
por: Kim, Serim, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
por: Kim, Chang Hee, et al.
Publicado: (2017)

Exposure–Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended‐Release Formulation
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2019)

Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open‐Label, 1‐Sequence, Crossover Studies
por: Groenendaal‐van de Meent, Dorien, et al.
Publicado: (2022)

A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects
por: Jung, Jin Ah, et al.
Publicado: (2015)

Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials
por: Muensterman, Elena, et al.
Publicado: (2021)

Pharmacokinetic and bioequivalence study comparing a fimasartan/rosuvastatin fixed-dose combination with the concomitant administration of fimasartan and rosuvastatin in healthy subjects
por: Kang, Woo Youl, et al.
Publicado: (2018)

Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2017)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Hwang, Sejung, et al.
Publicado: (2021)

Exposure–Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit–Risk Assessment in Rheumatoid Arthritis
por: Nader, Ahmed, et al.
Publicado: (2019)

Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
por: Hausner, Helene, et al.
Publicado: (2017)

Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects
por: Jordy, Andreas B., et al.
Publicado: (2021)

Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects
por: Woo, Hye In, et al.
Publicado: (2017)

Effect of Green Tea Extract and Soy Isoflavones on the Pharmacokinetics of Rosuvastatin in Healthy Volunteers
por: Zeng, Weiwei, et al.
Publicado: (2022)

In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin
por: Galani, VJ, et al.
Publicado: (2010)

Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects
por: Moon, Seol Ju, et al.
Publicado: (2019)

Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects
por: Csonka, Dénes, et al.
Publicado: (2019)

Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia
por: Abbas, Ahmed, et al.
Publicado: (2012)

A comparison of the effects of monotherapy with rosuvastatin, atorvastatin or ezetimibe versus combination treatment with rosuvastatin-ezetimibe and atorvastatin-ezetimibe on the integrity of vascular endothelial cells damaged by oxidized cholesterol
por: Niedzielski, Mateusz, et al.
Publicado: (2021)

Pharmacokinetic comparison of a fixed-dose combination versus concomitant administration of amlodipine, olmesartan, and rosuvastatin in healthy adult subjects
por: Oh, Minkyung, et al.
Publicado: (2019)

Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
por: Han, Eugene, et al.
Publicado: (2017)

No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug–Drug Interaction Study
por: Otani, Naoyuki, et al.
Publicado: (2019)

Antibacterial activity of statins: a comparative study of Atorvastatin, Simvastatin, and Rosuvastatin
por: Masadeh, Majed, et al.
Publicado: (2012)

Periodic Rosuvastatin or Atorvastatin Dosing Arrays (PRADA): Patient-Centered Practice
por: Christou, Theodore, et al.
Publicado: (2014)

The effects of treatment with atorvastatin versus rosuvastatin on endothelial dysfunction in patients with hyperlipidaemia
por: Vahit, Demir, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tb9moa7tfalcrri0b9mnf07ohb